Across TCGA pan-cancer cohorts, MED12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED12 data layer compared with 22 for mass-spec protein and 13 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MED12 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED12 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where MED12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.661	0.922	<.001	50	view →
LUAD	DFS	Quartile	All	0.982	0.813	.010	19	view →
LSCC	OS	Quartile	All	0.962	0.726	.005	18	view →
PDAC	DFS	Tertile	All	0.544	0.853	.006	13	view →
CCRCC	OS	Median	All	0.903	1.000	.019	8	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: MED12 tumor-vs-normal RNA expression · all MED12 data types